Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

J&J, Moderna sign deals with U.S. to produce huge quantity of possible coronavirus vaccines

Published 03/30/2020, 08:14 AM
Updated 03/30/2020, 07:10 PM
© Reuters. FILE PHOTO: The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company's listing at the NYSE in New York

© Reuters. FILE PHOTO: The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company's listing at the NYSE in New York

By Julie Steenhuysen

(Reuters) - The U.S. government has cut deals with Johnson & Johnson (N:JNJ) and Moderna Inc (O:MRNA) and said it is in talks with at least two other companies to prepare them to produce massive quantities of coronavirus vaccines even before safe and effective ones become available.

There are currently no approved treatments or vaccines specifically for COVID-19, the respiratory disease that has killed more than 35,000 people and infected over 745,000 globally in just a few months.

No vaccine is expected to be ready for use until at least 2021, as they must still be widely tested in humans before being administered to hundreds of millions, if not billions, of people to prevent infection.

On Monday, J&J announced a $1 billion deal with the U.S. government to create enough manufacturing capacity to make more than 1 billion doses of a vaccine, and its shares closed up 8% at $133.01.

It has chosen a candidate but will not begin testing it in people until September.

Moderna, which this month began very early tests of its vaccine candidate in people, also signed a deal with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services.

The arrangements are part of the federal government's effort to encourage drugmakers to be able to produce massive amounts of COVID-19 vaccines even before any are proven to work.

The J&J effort will be funded in part by about $420 million from BARDA. The agency told Reuters it also plans to spend an unnamed amount to ramp up manufacturing for Moderna's COVID-19 vaccine candidate.

Moderna shares rose 1.4% to $30.48.

BARDA ultimately plans to support five or six experimental vaccine candidates, with the hopes of having two or three successful ones, BARDA director Rick Bright said in a phone interview.

Experts have estimated it could be 12 to 18 months before a safe and effective vaccine wins regulatory approval.

"Government and industry is working in unprecedented ways," Bright said. The hope is to work "as quickly as possible and manufacture enough of it for us and the rest of the world in a very short timeframe."

The agency plans to take over manufacturing of Moderna's vaccine candidate to enable the Cambridge, Massachusetts-based biotech to focus on testing it in larger trials.

BARDA hopes to speed up the back end of the vaccine manufacturing process, which involves ensuring that they are made and packaged according to standards set by the U.S. Food and Drug Administration.

'A LOT OF RISK INVOLVED'

There are dozens of coronavirus vaccines in development, according to the World Health Organization. But it is still not clear that people develop lasting immunity to this virus, or what it will take for a vaccine to be protective.

"What you need to do is take an assessment of what the most likely candidates are and invest at risk in those," said Seth Berkley, chief executive of the Global Alliance for Vaccines and Immunization (GAVI).

The earlier you make that decision, the more likely you are to have manufacturing in place, but the less confident you are about whether the vaccine will work, Berkley said.

Typically, decisions on whether to move forward with a vaccine are made after safety trials and preliminary efficacy trials have been completed.

J&J said it will begin human testing in September, with an eye toward having a vaccine ready under an emergency use authorization in early 2021.

J&J Chief Scientific Officer Dr. Paul Stoffels told Reuters the company had to start ramping up manufacturing capacity now, even before it has a signal that its experimental vaccine candidate works.

"That is the only option for us to get it on time," Stoffels said of the early 2021 target. J&J hopes to have data proving its vaccine works by the end of this year.

J&J has a manufacturing plant in the Netherlands that can make up to 300 million doses of vaccine, Stoffels said, but that "absolutely will not be sufficient for the world."

The company is also scouting for manufacturing plants in other parts of Europe and Asia capable of making the type of vaccine the company is working on.

Stoffels said J&J's vaccine will be based on the same technology used to make its Ebola vaccine, which has been widely used in people. The company believes it will prove safe.

In lab studies, it has produced strong neutralizing antibodies to the virus - the type needed to make a successful vaccine.

In addition to the investments in J&J and Moderna, Bright said his agency is in talks with at least two other large vaccine makers, but declined to make them public.

BARDA is interested in working with a broad range of vaccine technologies and with companies that have proven track records, Bright said.

© Reuters. FILE PHOTO: A Johnson & Johnson building is shown in Irvine, California

"There's a lot of risk involved in making a new vaccine, a lot of risk in going quickly," Bright said. "Wherever possible, we need to understand and mitigate that risk."

Latest comments

O.K until September, after 300,000 U.S citizen passed away then get Vaccine. right? 150days remained, 20,000 newly infected everyday, then total patients will be 3 Million, death toll 1% is 300,000. It's too late to be a game changer.
but a money maker for them
its about money, profit. Governments must jump in, not private zones. people die, economy dies, profit and money makes no sense.
there advertising a false hope so stock market don't collapse. what makes them different then everyone else will not be till later half of 2021
China will progide the world with free vaccine. J&J go back to shampoo production and make sure it is safe for our kids
Yes, cancer from baby powder or j&j's shampoo, it doesnt matter how U.S companies make money or how many people gets killed
Really!! Are you talking free vacine direct from the Comunist Party to all with Love
Rubbish comment...Without the Technolgy Leader USA the world will be doomed. What China contributues to the World. Which big Technolgy Innovation comes from China in the last 4 Decades..? Even their bIggest Tech Companies are more or less Copys from US Gigants like FB/ Paypal etc.China bring us the Virus but for the relief of the Mess we must hope on the US as China and Europe not in an Position to fix any Problems even not that one that they create by themselfs..
The money is not in the cure, it is in the treatment
By Sep only testing stage?
BARDA ummm so its similar to DARPA now invading our bodies in addition to invasion of privacy , tnx but no tnx, bur what do i know they come up with a new patriot act making it mandatory
NWO is coming to all of us , what are we going to do about it ?
Vaccines aren't any good when the first side effect listed is may cause death better to spend the time testing then create more problems then it fixes. Beside even the flu vaccines aren't that good when you only have a 50/50 chance they actually work.
I bet you’re fun at parties
How??? It's a Vaccine.. so much process to formulate and then very long experimental procedure.. All it takes several months. Unavoidable.
Too slow... it should be ready by next month!
Cant push out vaccines that dont work. That creates false sense of security which makes the pandemic much much more worst.
To correctly make and test a vaccine, you need about 18 months. Anything ready before that is either untested (Google Thalidomide for nightmares)... or indicative that work on the vaccine started more than 1 year in the past (watch 1995's movie Outbreak for the implication).
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.